Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade

For the complete activity, including supporting material, please visit https://www.peervoice.com/FAN860. Presented by Austin Kulasekararaj, MD, MRCP, FRCPath; and Bruno Fattizzo, MD Learning Objectives: Discuss the criticality of achieving and sustaining terminal complement inhibition in patients with paroxysmal nocturnal haemoglobinuria (PNH), and the evidence for C5 inhibitor therapy on key efficacy outcomes; Recognise that extravascular haemolysis (EVH) is a potential limitation of terminal complement inhibition with C5 inhibitors and the need to target proximal complement blockade in patients with PNH who are experiencing clinically significant EVH (csEVH); Apply current clinical evidence to develop an optimised treatment strategy for patients with PNH experiencing csEVH while receiving C5 inhibitor therapy; Analyse and interpret the clinical evidence regarding severe breakthrough haemolysis in patients receiving proximal complement inhibition.

Listen